Related references
Note: Only part of the references are listed.Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients
Teresa M. Attina et al.
JOURNAL OF HYPERTENSION (2008)
Acute effects of a single dose of phosphodiesterase type 5 inhibitor (Sildenafil) on systemic arterial blood pressure during exercise and 24-hour ambulatory blood pressure monitoring in heart transplant recipients
G. V. Guimaraes et al.
TRANSPLANTATION PROCEEDINGS (2007)
Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility
Jayan Nagendran et al.
CIRCULATION (2007)
Erectile dysfunction and hypertension
R. Kloner
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH (2007)
The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems
E. R. Schwarz et al.
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH (2007)
Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke
Li Zhang et al.
BRAIN RESEARCH (2006)
Effect of regular phosphodiesterase type 5 inhibition in hypertension
James J. Oliver et al.
HYPERTENSION (2006)
Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension
Dean Patterson et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Phosphodiesterase-5 inhibitors and their hemodynamic effects
L. Michael Prisant
CURRENT HYPERTENSION REPORTS (2006)
Sildenafil citrate and sildenafil nitrate (NCX 911) are potent inhibitors of superoxide formation and gp91phox expression in porcine pulmonary artery endothelial cells
S Muzaffar et al.
BRITISH JOURNAL OF PHARMACOLOGY (2005)
Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis
A Das et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy
E Takimoto et al.
NATURE MEDICINE (2005)
Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system
DH Maurice et al.
MOLECULAR PHARMACOLOGY (2003)
Sildenafil and T-1032, phosphodiesterase type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta
H Mochida et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Share Paper
